Literature DB >> 23889002

Melatonin attenuates hypertension-related proarrhythmic myocardial maladaptation of connexin-43 and propensity of the heart to lethal arrhythmias.

Tamara Benova1, Csilla Viczenczova, Jana Radosinska, Barbara Bacova, Vladimir Knezl, Victor Dosenko, Peter Weismann, Michal Zeman, Jana Navarova, Narcis Tribulova.   

Abstract

We hypothesized that the pineal hormone melatonin, which exhibits cardioprotective effects, might affect myocardial expression of cell-to-cell electrical coupling protein connexin-43 (Cx43) and protein kinase C (PKC) signaling, and hence, the propensity of the heart to lethal ventricular fibrillation (VF). Spontaneously hypertensive (SHR) and normotensive Wistar rats fed a standard rat chow received melatonin (40 μg/mL in drinking water during the night) for 5 weeks, and were compared with untreated rats. Melatonin significantly reduced blood pressure and normalized triglycerides in SHR, whereas it decreased body mass and adiposity in Wistar rats. Compared with healthy rats, the threshold to induce sustained VF was significantly lower in SHR (18.3 ± 2.6 compared with 29.2 ± 5 mA; p < 0.05) and increased in melatonin-treated SHR and Wistar rats to 33.0 ± 4 and 32.5 ± 4 mA. Melatonin attenuated abnormal myocardial Cx43 distribution in SHR, and upregulated Cx43 mRNA, total Cx43 protein, and its functional phosphorylated forms in SHR, and to a lesser extent, in Wistar rat hearts. Moreover, melatonin suppressed myocardial proapoptotic PKCδ expression and increased cardioprotective PKCε expression in both SHR and Wistar rats. Our findings indicate that melatonin protects against lethal arrhythmias at least in part via upregulation of myocardial Cx43 and modulation of PKC-related cardioprotective signaling.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23889002     DOI: 10.1139/cjpp-2012-0393

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  19 in total

Review 1.  Effects of melatonin on cardiovascular risk factors and metabolic syndrome: a comprehensive review.

Authors:  Mohsen Imenshahidi; Golamreza Karimi; Hossein Hosseinzadeh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-01-30       Impact factor: 3.000

2.  Obesity-associated alterations in cardiac connexin-43 and PKC signaling are attenuated by melatonin and omega-3 fatty acids in female rats.

Authors:  Tamara Egan Benova; Csilla Viczenczova; Barbara Szeiffova Bacova; Vladimir Knezl; Victor Dosenko; Hana Rauchova; Michal Zeman; Russel J Reiter; Narcis Tribulova
Journal:  Mol Cell Biochem       Date:  2018-11-16       Impact factor: 3.396

Review 3.  Dysregulation of Mfn2 and Drp-1 proteins in heart failure.

Authors:  Srikanth Givvimani; Sathnur Pushpakumar; Sudhakar Veeranki; Suresh C Tyagi
Journal:  Can J Physiol Pharmacol       Date:  2014-05-09       Impact factor: 2.273

Review 4.  Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection.

Authors:  Rainer Schulz; Philipp Maximilian Görge; Anikó Görbe; Péter Ferdinandy; Paul D Lampe; Luc Leybaert
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

Review 5.  Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications.

Authors:  Luc Leybaert; Paul D Lampe; Stefan Dhein; Brenda R Kwak; Peter Ferdinandy; Eric C Beyer; Dale W Laird; Christian C Naus; Colin R Green; Rainer Schulz
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

6.  Therapeutic potential of a single-dose melatonin in the attenuation of cardiac ischemia/reperfusion injury in prediabetic obese rats.

Authors:  Kodchanan Singhanat; Nattayaporn Apaijai; Natticha Sumneang; Chayodom Maneechote; Busarin Arunsak; Titikorn Chunchai; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Cell Mol Life Sci       Date:  2022-05-19       Impact factor: 9.261

7.  Altered thyroid status affects myocardial expression of connexin-43 and susceptibility of rat heart to malignant arrhythmias that can be partially normalized by red palm oil intake.

Authors:  Barbara Szeiffová Bačová; Csilla Vinczenzová; Jitka Žurmanová; Dita Kašparová; Vladimír Knezl; Tamara Egan Beňová; Stanislav Pavelka; Tomáš Soukup; Narcisa Tribulová
Journal:  Histochem Cell Biol       Date:  2016-09-06       Impact factor: 4.304

8.  Hypertension and cardiovascular remodelling in rats exposed to continuous light: protection by ACE-inhibition and melatonin.

Authors:  Fedor Simko; Olga Pechanova; Kristina Repova Bednarova; Kristina Krajcirovicova; Peter Celec; Natalia Kamodyova; Stefan Zorad; Jarmila Kucharska; Anna Gvozdjakova; Michaela Adamcova; Ludovit Paulis
Journal:  Mediators Inflamm       Date:  2014-07-06       Impact factor: 4.711

Review 9.  Clinical Application of Melatonin in the Treatment of Cardiovascular Diseases: Current Evidence and New Insights into the Cardioprotective and Cardiotherapeutic Properties.

Authors:  Mohammad Hossein Pourhanifeh; Ehsan Dehdashtian; Azam Hosseinzadeh; Seyed Hashem Sezavar; Saeed Mehrzadi
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-14       Impact factor: 3.727

Review 10.  Effects of melatonin on cardiovascular diseases: progress in the past year.

Authors:  Hang Sun; Aaron M Gusdon; Shen Qu
Journal:  Curr Opin Lipidol       Date:  2016-08       Impact factor: 4.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.